welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Frank C. Sciavolino, Ph.D., Chief Scientific Officer, will present an overview of TP-252, the Company’s investigational drug candidate for the treatment of familial adenomatous polyposis (FAP) at the 2016 World Orphan Drug Congress USA. The presentation will take place at the Washington Hilton in Washington, D.C. at 3 pm (EDT) on April 21, 2016.
expertly curated content related to this topic
-
PTSD common in patients with familial adenomatous polyposisPosttraumatic stress disorder is common ...
-
Osamu ItanoOsamu Itano works in departement of Gas...
-
Familial Adenomatous Polyposis; 30-Year Observation of a Female Patient – Case ReportFamilial Adenomatous Polyposis (FAP) is ...
-
Penn Medicine – Abramson Cancer CenterPenn Medicine’s Abramson Cancer Center...
-
Columbia University Medical CenterUsing specialized techniques to connect ...
-
St. Mark’s Hospital/Polyposis RegistryPatient Resources: Polyposis Regist...
-
Cancer Insurance ChecklistThe Cancer Insurance Checklist is design...